Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

Top-line data indicate statistically significant improvement in ACR20 responses over placebo

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint. The top-line results from the recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated that when compared to placebo, three times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks, the primary endpoint of the study, as measured by the American College of Rheumatology (ACR) 20 measurement of response. These results were statistically significant when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

"We are greatly encouraged by this demonstration of efficacy from a well-designed and well-executed study," said Howard H. Pien, Chairman and CEO of Medarex. "These results show that by targeting the chemokine IP-10 with our MDX-1100 antibody, we may be able to offer a potentially important and novel treatment option for rheumatoid arthritis and potentially other inflammatory indications."

"Based on these positive results with a novel pro-inflammatory target, we are actively preparing for the next stage of clinical development for MDX-1100 in RA, including the potential for subcutaneous dosing," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We also look forward to exploring the broader potential of MDX-1100 in a range of i
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... S.C., April 12, 2011 Southern Home Medical ... healthcare services, healthcare professionals and equipment to medical ... results from operations for fiscal year 2010 have ... from Encore Medical Staffing. In a ...
... ST. PAUL, Minn., April 12, 2011 According to ... safety edit, designed to require provider prior authorization (PA) ... use of insulin or nitrate (CIN), potentially decreased members, ... at the Academy of Managed Care Pharmacy,s 23rd Annual ...
Cached Medicine Technology:Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2Point-of-Sale Electronic Safety Check May Reduce Heart Attack Risk for Diabetic Patients 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out ... summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire ... heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , , TAMPA, Fla., July 23 ... scrubs and chemical drugs and armed himself with a movie ... due to preventable illness, Burton found an alarming connection between ... of death. Now he,s going to tell the world what ...
... recent years. This is fact, but what is not clear ... have shown that family conflict is not a significant factor. ... striking: in Spain, 24% of women take antidepressants and more ... is often related to family or work-related problems. We wanted ...
... Ind., July 23 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) ... 2009. You are invited to participate in a webcast the following ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Third Quarter ... the public after the NYSE close on Thursday, August 6, 2009. ...
... YORK, July 23 The U.S. Fund for UNICEF announced today ... UNICEF,s mission to save, protect and improve the lives of children ... reducing the number of preventable deaths of children, from 25,000 per ... will lead the steering committee and host UNICEF,s Next Generation launch ...
... July 23 At the 2009 American Association of ... Anaheim, California, Elekta will demonstrate how the company,s comprehensive ... cancer care with precision and ease. , , ... deliver radiation treatments, Elekta booth 423 will highlight treatment ...
... , WARREN, N.J., July 23 MonoSol Rx, the ... dissolving thin film pharmaceutical products, today announced the appointment of Theodore ... will report to Keith J. Kendall, Executive Vice President and CFO. ... are pleased to welcome Ted to MonoSol Rx and look forward ...
Cached Medicine News:Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2Health News:U.S. Fund for UNICEF and Jenna Bush Hager Announce Next Generation Initiative to Improve Lives of Children Around the World 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 2Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 3
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: